Trial Profile
Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms REFALS
- Sponsors Orion; Orion Pharma
- 22 Apr 2021 Results assessing how clinical chemistry measurements from the REFALS trial correlate with amyotrophic lateral sclerosis disease course to elucidate their potential as biomarkers of disease, presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 22 Apr 2021 Results assessing the association of baseline characteristics with response to levosimendan in people with amyotrophic lateral sclerosis (ALS), were presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 09 Oct 2020 Status changed from active, no longer recruiting to completed.